S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
S&P 500   3,768.47
DOW   30,924.14
QQQ   304.10
Log in
NASDAQ:AXLA

Axcella Health Competitors

$5.51
-0.17 (-2.99 %)
(As of 03/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.50
Now: $5.51
$5.73
50-Day Range
$5.21
MA: $5.98
$6.72
52-Week Range
$2.25
Now: $5.51
$7.73
Volume111,624 shs
Average Volume79,299 shs
Market Capitalization$206.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53

Competitors

Axcella Health (NASDAQ:AXLA) Vs. ALGS, CLLS, TCRR, STRO, ADAP, and VXRT

Should you be buying AXLA stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Axcella Health, including Aligos Therapeutics (ALGS), Cellectis (CLLS), TCR2 Therapeutics (TCRR), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), and Vaxart (VXRT).

Aligos Therapeutics (NASDAQ:ALGS) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Aligos Therapeutics and Axcella Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aligos TherapeuticsN/AN/AN/A
Axcella HealthN/A-79.03%-54.77%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Aligos Therapeutics and Axcella Health, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aligos Therapeutics00403.00
Axcella Health01802.89

Aligos Therapeutics presently has a consensus target price of $30.50, indicating a potential upside of 41.60%. Axcella Health has a consensus target price of $17.1250, indicating a potential upside of 210.80%. Given Axcella Health's higher probable upside, analysts plainly believe Axcella Health is more favorable than Aligos Therapeutics.

Valuation and Earnings

This table compares Aligos Therapeutics and Axcella Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aligos TherapeuticsN/AN/AN/AN/AN/A
Axcella HealthN/AN/A$-59,040,000.00($3.55)-1.55

Institutional and Insider Ownership

66.8% of Axcella Health shares are owned by institutional investors. 10.4% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Axcella Health beats Aligos Therapeutics on 4 of the 7 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Cellectis has a beta of 2.59, suggesting that its stock price is 159% more volatile than the S&P 500. Comparatively, Axcella Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Profitability

This table compares Cellectis and Axcella Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
Axcella HealthN/A-79.03%-54.77%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cellectis and Axcella Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis11302.40
Axcella Health01802.89

Cellectis currently has a consensus price target of $24.25, indicating a potential upside of 25.58%. Axcella Health has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Given Axcella Health's stronger consensus rating and higher probable upside, analysts clearly believe Axcella Health is more favorable than Cellectis.

Earnings & Valuation

This table compares Cellectis and Axcella Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million35.69$-102,090,000.00($2.41)-8.01
Axcella HealthN/AN/A$-59,040,000.00($3.55)-1.55

Axcella Health has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

33.3% of Cellectis shares are owned by institutional investors. Comparatively, 66.8% of Axcella Health shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 10.4% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Axcella Health beats Cellectis on 7 of the 13 factors compared between the two stocks.

TCR2 Therapeutics (NASDAQ:TCRR) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

TCR2 Therapeutics has a beta of 2.13, suggesting that its stock price is 113% more volatile than the S&P 500. Comparatively, Axcella Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Profitability

This table compares TCR2 Therapeutics and Axcella Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TCR2 TherapeuticsN/A-35.51%-34.02%
Axcella HealthN/A-79.03%-54.77%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for TCR2 Therapeutics and Axcella Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TCR2 Therapeutics00703.00
Axcella Health01802.89

TCR2 Therapeutics currently has a consensus price target of $39.2857, indicating a potential upside of 63.28%. Axcella Health has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Given Axcella Health's higher probable upside, analysts clearly believe Axcella Health is more favorable than TCR2 Therapeutics.

Earnings & Valuation

This table compares TCR2 Therapeutics and Axcella Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TCR2 TherapeuticsN/AN/A$-47,600,000.00($4.62)-5.21
Axcella HealthN/AN/A$-59,040,000.00($3.55)-1.55

TCR2 Therapeutics is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

82.1% of TCR2 Therapeutics shares are owned by institutional investors. Comparatively, 66.8% of Axcella Health shares are owned by institutional investors. 28.0% of TCR2 Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

TCR2 Therapeutics beats Axcella Health on 7 of the 11 factors compared between the two stocks.

Sutro Biopharma (NASDAQ:STRO) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Sutro Biopharma and Axcella Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sutro Biopharma27.60%-41.86%-29.50%
Axcella HealthN/A-79.03%-54.77%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Sutro Biopharma and Axcella Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sutro Biopharma01602.86
Axcella Health01802.89

Sutro Biopharma currently has a consensus price target of $23.3333, indicating a potential upside of 15.00%. Axcella Health has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Given Axcella Health's stronger consensus rating and higher probable upside, analysts clearly believe Axcella Health is more favorable than Sutro Biopharma.

Volatility and Risk

Sutro Biopharma has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Axcella Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Institutional & Insider Ownership

78.8% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 66.8% of Axcella Health shares are owned by institutional investors. 28.9% of Sutro Biopharma shares are owned by company insiders. Comparatively, 10.4% of Axcella Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Sutro Biopharma and Axcella Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sutro Biopharma$42.74 million18.33$-55,740,000.00($2.43)-8.35
Axcella HealthN/AN/A$-59,040,000.00($3.55)-1.55

Sutro Biopharma has higher revenue and earnings than Axcella Health. Sutro Biopharma is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Summary

Sutro Biopharma beats Axcella Health on 8 of the 13 factors compared between the two stocks.

Axcella Health (NASDAQ:AXLA) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares Axcella Health and Adaptimmune Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axcella HealthN/A-79.03%-54.77%
Adaptimmune Therapeutics-3,858.14%-44.94%-33.70%

Analyst Recommendations

This is a summary of recent ratings for Axcella Health and Adaptimmune Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axcella Health01802.89
Adaptimmune Therapeutics03202.40

Axcella Health currently has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Adaptimmune Therapeutics has a consensus price target of $15.50, indicating a potential upside of 209.38%. Given Axcella Health's stronger consensus rating and higher probable upside, equities research analysts plainly believe Axcella Health is more favorable than Adaptimmune Therapeutics.

Risk and Volatility

Axcella Health has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500.

Institutional & Insider Ownership

66.8% of Axcella Health shares are owned by institutional investors. Comparatively, 99.8% of Adaptimmune Therapeutics shares are owned by institutional investors. 10.4% of Axcella Health shares are owned by insiders. Comparatively, 18.9% of Adaptimmune Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Axcella Health and Adaptimmune Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axcella HealthN/AN/A$-59,040,000.00($3.55)-1.55
Adaptimmune Therapeutics$1.12 million692.36$-137,160,000.00($1.32)-3.80

Axcella Health has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Summary

Adaptimmune Therapeutics beats Axcella Health on 7 of the 13 factors compared between the two stocks.

Axcella Health (NASDAQ:AXLA) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Profitability

This table compares Axcella Health and Vaxart's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Axcella HealthN/A-79.03%-54.77%
Vaxart-281.50%-84.90%-44.67%

Analyst Recommendations

This is a summary of recent ratings for Axcella Health and Vaxart, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Axcella Health01802.89
Vaxart00203.00

Axcella Health currently has a consensus price target of $17.1250, indicating a potential upside of 210.80%. Vaxart has a consensus price target of $15.00, indicating a potential upside of 153.38%. Given Axcella Health's higher probable upside, equities research analysts plainly believe Axcella Health is more favorable than Vaxart.

Risk and Volatility

Axcella Health has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Vaxart has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500.

Institutional & Insider Ownership

66.8% of Axcella Health shares are owned by institutional investors. Comparatively, 17.9% of Vaxart shares are owned by institutional investors. 10.4% of Axcella Health shares are owned by insiders. Comparatively, 7.3% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Axcella Health and Vaxart's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axcella HealthN/AN/A$-59,040,000.00($3.55)-1.55
Vaxart$9.86 million70.71$-18,650,000.00($0.86)-6.88

Vaxart has higher revenue and earnings than Axcella Health. Vaxart is trading at a lower price-to-earnings ratio than Axcella Health, indicating that it is currently the more affordable of the two stocks.

Summary

Axcella Health beats Vaxart on 8 of the 13 factors compared between the two stocks.


Axcella Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.54-12.1%$821.06 millionN/A0.00
Cellectis logo
CLLS
Cellectis
1.2$19.31-4.3%$820.41 million$22.99 million-10.27
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.5$24.06-6.9%$804.13 millionN/A-9.94
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.29-4.7%$783.28 million$42.74 million-225.44
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.01-4.8%$775.44 million$1.12 million-5.06Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$5.92-7.4%$697.18 million$9.86 million-10.03Analyst Report
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.86-7.3%$667.23 million$2.51 million-4.16Earnings Announcement
Analyst Report
Increase in Short Interest
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.29-6.8%$626.64 millionN/A0.00Decrease in Short Interest
News Coverage
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.4$30.61-8.2%$622.00 millionN/A0.00Increase in Short Interest
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.16-7.3%$600.87 million$150.05 million-2.90
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$11.02-3.1%$578.33 million$22.24 million-5.48Upcoming Earnings
Analyst Report
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.9$9.28-17.0%$573.69 millionN/A-1.35
Compugen logo
CGEN
Compugen
1.4$8.16-9.2%$558.31 million$17.80 million-22.05Analyst Downgrade
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.02-7.6%$551.49 million$14.75 million-2.15Gap Up
Curis logo
CRIS
Curis
1.3$9.13-6.4%$537.00 million$10 million-11.13Increase in Short Interest
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.90-2.5%$533.93 million$13.29 million-9.86Upcoming Earnings
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$8.83-12.0%$533.77 millionN/A-4.29Upcoming Earnings
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.7$20.44-2.7%$529.60 millionN/A-5.89
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.4$11.45-6.7%$519.76 million$147.87 million-3.80Analyst Upgrade
Gap Up
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$13.59-1.8%$513.21 million$4.36 million-4.75Upcoming Earnings
Increase in Short Interest
HARP
Harpoon Therapeutics
1.5$19.14-4.3%$485.77 million$5.78 million-8.99Upcoming Earnings
News Coverage
Gap Up
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$11.43-2.8%$476.93 millionN/A0.00Upcoming Earnings
Opthea logo
OPT
Opthea
1.5$9.35-7.0%$394.65 millionN/A0.00Decrease in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$19.75-0.0%$384.69 million$340,000.00-6.98
AVROBIO logo
AVRO
AVROBIO
1.7$10.54-4.6%$384.19 millionN/A-3.19
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.5$13.50-7.9%$349.93 millionN/A0.00High Trading Volume
Gap Down
Codiak BioSciences logo
CDAK
Codiak BioSciences
1.9$15.82-2.5%$347.25 millionN/A0.00Analyst Upgrade
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$9.18-10.1%$340.14 million$250,000.00-3.28Analyst Revision
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.30-2.1%$339.62 million$96.12 million-12.65Upcoming Earnings
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$3.71-6.2%$329.60 millionN/A-5.80High Trading Volume
Decrease in Short Interest
News Coverage
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.25-7.4%$329.00 millionN/A0.00Upcoming Earnings
Increase in Short Interest
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$6.20-3.4%$323.95 million$2.91 million-2.16Increase in Short Interest
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.81-11.0%$313.91 million$8.15 million-1.45Decrease in Short Interest
Surface Oncology logo
SURF
Surface Oncology
1.3$7.53-12.5%$306.30 million$15.36 million-11.41Upcoming Earnings
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$9.24-8.3%$300.60 millionN/A-3.80Upcoming Earnings
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.3$13.50-7.9%$290.94 millionN/A0.00
PDL BioPharma logo
PDLI
PDL BioPharma
1.1$2.47-0.0%$282.14 million$54.76 million-2.19Upcoming Earnings
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$2.18-9.6%$270.20 million$4.13 million-4.84News Coverage
Cabaletta Bio logo
CABA
Cabaletta Bio
1.5$10.39-11.3%$249.93 millionN/A-7.58
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$7.84-6.8%$249.20 millionN/A-4.90Analyst Report
News Coverage
Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$5.06-7.1%$215.85 million$2.45 million-2.38Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$2.23-5.4%$210.84 million$29.35 million-2.59Upcoming Earnings
News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$5.58-0.7%$210.11 million$104.39 million-3.40
INmune Bio logo
INMB
INmune Bio
1.5$15.37-22.5%$206.70 millionN/A-15.85Earnings Announcement
News Coverage
Gamida Cell logo
GMDA
Gamida Cell
1.4$8.43-6.3%$204.18 millionN/A-5.90Upcoming Earnings
Increase in Short Interest
Gap Up
Genfit logo
GNFT
Genfit
1.3$4.87-2.7%$189.24 million$45.88 million-2.47
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$7.18-6.7%$186.70 millionN/A-8.76Gap Up
Idera Pharmaceuticals logo
IDRA
Idera Pharmaceuticals
1.4$4.23-14.2%$178.75 million$1.45 million-1.48Earnings Announcement
Analyst Upgrade
Increase in Short Interest
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$8.90-0.7%$178.60 millionN/A-2.27Gap Up
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$5.35-4.3%$168.68 million$20,000.000.00Decrease in Short Interest
Gap Down
This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.